Related Experiment Videos

[Endovascular treatment for carotid artery stenosis]

H Gensicke1, S Engelter, L Bonati

  • 1Neurologie, Stroke Unit, Universitätsspital Basel.

Insights

Carotid endarterectomy (CEA) is safer for symptomatic carotid stenosis than carotid artery stenting (CAS), especially for those over 70. Both treatments effectively prevent stroke, but restenosis is more common after CAS.

Area of Science:

  • Vascular Surgery
  • Neurology
  • Interventional Cardiology

Context:

  • Internal carotid artery (ICA) stenosis causes 10-15% of ischemic strokes.
  • Carotid endarterectomy (CEA) is the standard treatment for symptomatic carotid stenosis, reducing recurrent stroke risk.
  • Endovascular techniques like carotid artery stenting (CAS) offer surgical alternatives.

Purpose:

  • To compare the risks and benefits of CAS versus CEA for carotid stenosis.
  • To summarize evidence from randomized controlled trials on CAS and CEA outcomes.

Summary:

  • For symptomatic carotid stenosis, CEA has a lower risk of peri-procedural stroke or death compared to CAS.
  • CAS shows reduced risks of myocardial infarction, cranial nerve palsy, and access site hematoma versus CEA.
  • CAS is as safe as CEA in patients under 70; however, CAS carries higher stroke risk in older patients (>70).
  • Both treatments are equally effective in preventing recurrent stroke in the short term.
  • Restenosis is more frequent after CAS, necessitating longer-term follow-up.

Impact:

  • CEA is recommended for symptomatic carotid stenosis, particularly in older patients, due to lower peri-procedural risks.
  • CAS may be a safer alternative for younger patients or those with specific contraindications to CEA.
  • Further research is needed to determine the optimal treatment for asymptomatic carotid stenosis and long-term outcomes of CAS.
  • Evidence supports CAS for reducing specific complications like myocardial infarction and nerve palsy.
  • Understanding long-term restenosis rates after CAS is crucial for guiding treatment decisions.

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...